Last Updated Jan 12, 2010 3:16 PM EST
The company -- which has been fantastically profitable because of its specialty in HIV drugs -- may want to consider whether it should end its recent flirtation with heart drugs. Both of them have run into expensive problems recently.
In December it emerged that darusentan, Gilead's blood pressure candidate, not only was associated with heart problems but also missed a primary endoint in testing. Most observers, such as The Motley Fool, took this as bad news:
The loss of darusentan is a major blow to Gilead's diversification away from its HIV franchise. It still has a decent pipeline of non-HIV drugs, but most are in phase 1 or 2 testing, so it'll be quite awhile before HIV drugs aren't the main contributor to Gilead's revenue.In fact, the cloud may have a silver lining. This is an opportunity for Gilead to get back to its knitting on HIV, instead of trying to turn itself into Pfizer (PFE), with all sorts of mainstream non-specialist drugs. (Even Pfizer is backing away from that model.) Those drugs may be popular, but they have higher per-pill marketing expenses.
Gilead's other heart drug, Ranexa for chronic angina, is under investigation by the Department of Justice. The feds want to know if there was anything wrong with Gilead's acquisition of CV Therapeutics, which owned the drug. Even if Gilead emerges unscathed from the probe, the company still has to make a profit on the drug. It paid $1.4 billion to acquire CVT; Ranexa thus far makes only $49 million a quarter (it's not a first-line treatment for angina).
It may indeed be the case that there will be an uncomfortable gap in Gilead's pipeline, but the company's long-run value is in its specialty, not its me-too drugs.
- Gilead Subpoena Will Have Investors Guessing: What's Wrong With the CVT Acquisition?
- Gilead Axes 139 Jobs in Colorado; CVT Reps Get Culture Shock
- Gilead Q2 Mystery: Purchase of Less-Efficient CVT Made It a More Efficient Company
- Ranking of 20 Drug Companies by Sales Force Effectiveness Shows Improvement in Q1
- Gilead Q1: Company Is Recession Resistant But Not Lawsuit Resistant
- With New CV Drugs, Gilead Tests Its Commitment to Efficiency
- Gilead Executive Pay: Modest Raises for Outstanding Performance
- Gilead Deal Gives CV Therapeutics CEO $8.4 Million Payday Despite Lack of Profits